TSHA logo

Taysha Gene Therapies Community

NasdaqGS:TSHA Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 13 Fair Values set on narratives written by author

Community Investing Ideas

TSHA logo
Taysha Gene Therapies

FDA Meetings And TSHA-102 Trials Will Advance Approval

Key Takeaways Advancements in TSHA-102 trials and regulatory discussions could expedite approval and boost future revenue and investor confidence. Strategic alignment with regulatory and market priorities could enhance trial success, market adoption, and long-term revenue growth.
View narrative
US$8.32
FV
64.7% undervalued intrinsic discount
123.23%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
19 days ago author updated this narrative